PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
about
Therapeutic Antibodies against Intracellular Tumor AntigensExpression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.New Approaches to Difficult Drug Targets: The Phosphatase StoryChemotherapy induced PRL3 expression promotes cancer growth via plasma membrane remodeling and specific alterations of caveolae-associated signaling
P2860
Q41462883-A0ECC474-9CC1-435C-BF71-F7003A4E2C1DQ47123783-9720ABE6-645A-410C-8980-B05B6497E203Q47881716-DC6B3589-BC29-45B8-BB39-8E1E6E3F6A9AQ47956417-509FE0C6-4D65-4B48-97B5-99108454F939Q48103763-0B9DB620-66CE-40E5-AA29-D72FC7A78FC9Q56513340-B7A0552B-FF98-49EB-B131-853BDF1A2CF1Q58694966-481E1E04-9306-4416-BC20-1FC78D700DE5
P2860
PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
@en
PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
@nl
type
label
PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
@en
PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
@nl
prefLabel
PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
@en
PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
@nl
P2093
P2860
P1433
P1476
PRL3-zumab, a first-in-class humanized antibody for cancer therapy
@en
P2093
Abdul Qader Omer Al-Aidaroos
Abhishek Gupta
Boon Cher Goh
Cheng William Hong
Hiu Fung Yuen
Hyun Cheol Chung
Jean Paul Thiery
P2860
P304
P356
10.1172/JCI.INSIGHT.87607
P577
2016-06-16T00:00:00Z